Eledon Pharmaceuticals, Inc. financial data

Symbol
ELDN on Nasdaq
Location
Irvine, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 982% % -4%
Debt-to-equity 89% %
Return On Equity -154% % -389%
Return On Assets -52% % -143%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59,932,212 shares 0.32%
Common Stock, Shares, Outstanding 59,881,775 shares 45%
Entity Public Float $64,885,717 USD 153%
Common Stock, Value, Issued $60,000 USD 46%
Weighted Average Number of Shares Outstanding, Basic 77,156,068 shares 49%
Weighted Average Number of Shares Outstanding, Diluted 77,156,068 shares 39%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $66,704,000 USD 62%
General and Administrative Expense $19,759,000 USD 31%
Operating Income (Loss) $19,070,000 USD 7%
Net Income (Loss) Attributable to Parent $79,787,000 USD -268%
Earnings Per Share, Basic 0 USD/shares 55%
Earnings Per Share, Diluted 0 USD/shares 25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,669,000 USD -46%
Cash, Cash Equivalents, and Short-term Investments $93,400,000 USD 19%
Other Assets, Current $14,000 USD -97%
Assets, Current $96,301,000 USD 18%
Operating Lease, Right-of-Use Asset $694,000 USD 47%
Other Assets, Noncurrent $476,000 USD 127%
Assets $129,857,000 USD 13%
Accounts Payable, Current $4,627,000 USD -21%
Liabilities, Current $14,296,000 USD 14%
Deferred Income Tax Liabilities, Net $2,183,000 USD 25%
Operating Lease, Liability, Noncurrent $376,000 USD 19%
Liabilities $38,803,000 USD 0.74%
Accumulated Other Comprehensive Income (Loss), Net of Tax $9,000 USD -91%
Retained Earnings (Accumulated Deficit) $390,756,000 USD -26%
Stockholders' Equity Attributable to Parent $35,360,000 USD 74%
Liabilities and Equity $129,857,000 USD 13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $16,060,000 USD -84%
Net Cash Provided by (Used in) Financing Activities $115,000 USD
Net Cash Provided by (Used in) Investing Activities $3,892,000 USD -60%
Common Stock, Shares Authorized 300,000,000 shares 50%
Common Stock, Shares, Issued 59,881,775 shares 45%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $12,053,000 USD -1256%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,669,000 USD -46%
Deferred Tax Assets, Valuation Allowance $46,379,000 USD 51%
Deferred Tax Assets, Gross $52,037,000 USD 41%
Operating Lease, Liability $722,000 USD 44%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $17,402,000 USD -123%
Lessee, Operating Lease, Liability, to be Paid $795,000 USD 39%
Operating Lease, Liability, Current $346,000 USD 86%
Lessee, Operating Lease, Liability, to be Paid, Year Two $293,000 USD 49%
Lessee, Operating Lease, Liability, to be Paid, Year One $403,000 USD 111%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $73,000 USD 4.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three $293,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $22,740,000 USD 26%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $6,232,000 USD 71%
Operating Lease, Payments $97,000 USD -4.9%
Share-based Payment Arrangement, Expense $14,568,000 USD 77%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%